Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -

NCT03496402 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT03496402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03496402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 20, 2018
Completion date
August 19, 2027
Enrollment
600 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system tumor, ewing sarcoma family of tumors, leukemia, neuroblastoma, osteosarcoma, rhabdomyosarcoma